Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

son V, Hamada H, Pardoll D, Mulligan
RC. Vaccination with irradiated tumor
cells engineered to secrete murine
granulocyte-macrophage colony-stimulating
factor stimulates potent, specific,
and long-lasting anti-tumor immunity.
Proc Natl Acad Sci USA 1993; 90: 3539±
43.
128 Baskar S, Ostrand-Rosenberg S, Nabavi
N, Nadler LM, Freeman GJ,
Glimcher LH. Constitutive expression
of B7 restores immunogenicity of tumor
cells expressing truncated major
histocompatibility complex class II molecules.
Proc Natl Acad Sci USA 1993;
90: 5687±90.
129 Pardoll DM. Cancer vaccines. Nat Med
1998; 4: 525±31.
130 Chen JL, Dunbar PR, Gileadi U,
Jager E, Gnjatic S, Nagata Y,
Stockert E, Panicali DL, Chen YT,
Knuth A, Old LJ, Cerundolo V. Identification
of NY-ESO-1 peptide analogues
capable of improved stimulation
of tumor-reactive CTL. J Immunol 2000;
165: 948±55.
131 Salgaller ML, Marincola FM, Cormier
JN, Rosenberg SA. Immunization
against epitopes in the human
melanoma antigen gp100 following patient
immunization with synthetic peptides.
Cancer Res 1996; 56: 4749±57.
132 Cormier JN, Salgaller ML, Prevette T,
Barracchini KC, Rivoltini L, Restifo
NP, Rosenberg SA, Marincola FM.
Enhancement of cellular immunity in
melanoma patients immunized with a
peptide from MART-1/Melan A. Cancer J
Sci Am 1997; 3: 37±44.
133 Rosenberg SA,Yang JC, Schwartzentruber
DJ, Hwu P, Marincola FM,
Topalian SL, Restifo NP, Dudley ME,
Schwarz SL, Spiess PJ, Wunderlich
JR, Parkhurst MR, Kawakami Y,
Seipp CA, Einhorn JH,White DE.
Immunologic and therapeutic evaluation
of a synthetic peptide vaccine for
the treatment of patients with metastatic
melanoma. Nat Med 1998; 4:
321±7.
134 Marchand M, van Baren N, Weynants
P, Brichard V, Dreno B, Tessier
MH, Rankin E, Parmiani G, Arienti
F, Humblet Y, Bourlond A,
References
Vanwijck R, Lienard D, Beauduin M,
Dietrich PY, Russo V, Kerger J, Masucci
G, Jager E, De Greve J, Atzpodien
J, Brasseur F, Coulie PG, van
der Bruggen P, Boon T. Tumor regressions
observed in patients with metastatic
melanoma treated with an antigenic
peptide encoded by gene MAGE-
3 and presented by HLA-A1. Int J Cancer
1999; 80: 219±30.
135 Valmori D, Romero JF, Men Y, Maryanski
JL, Romero P, Corradin G.
Induction of a cytotoxic T cell response
by co-injection of a T helper peptide
and a cytotoxic T lymphocyte peptide in
incomplete Freund's adjuvant (IFA):
further enhancement by pre-injection
of IFA alone. Eur J Immunol 1994; 24:
1458±62.
136 Corr M, Lee DJ, Carson DA, Tighe H.
Gene vaccination with naked plasmid
DNA: mechanism of CTL priming. J
Exp Med 1996; 184: 1555±60.
137 Corr M, Tighe H, Lee D, Dudler J,
Trieu M, Brinson DC, Carson DA.
Costimulation provided by DNA immunization
enhances antitumor immunity.
J Immunol 1997; 159: 4999±5004.
138 Rosenberg SA, Zhai Y,Yang JC,
Schwartzentruber DJ, Hwu P, Marincola
FM, Topalian SL, Restifo NP,
Seipp CA, Einhorn JH, Roberts B,
White DE. Immunizing patients with
metastatic melanoma using recombinant
adenoviruses encoding MART-1 or
gp100 melanoma antigens. J Natl Cancer
Inst 1998; 90: 1894±900.
139 Brossart P, Goldrath AW, Butz EA,
Martin S, Bevan MJ. Virus-mediated
delivery of antigenic epitopes into dendritic
cells as a means to induce CTL.
J Immunol 1997; 158: 3270±6.
140 Mukherji B, Chakraborty NG,Yamasaki
S, Okino T,Yamase H, Sporn JR,
Kurtzman SK, Ergin MT, Ozols J,
Meehan J, Mauri F. Induction of antigen-specific
cytolytic T cells in situ in
human melanoma by immunization
with synthetic peptide-pulsed autologous
antigen presenting cells. Proc Natl
Acad Sci USA 1995; 92: 8078±82.
141 Celluzzi CM, Mayordomo JI, Storkus
WJ, Lotze MT, Falo LD Jr. Peptide-pulsed
dendritic cells induce anti-
249